Cleave Therapeutics
Manufacturing · California, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
135 Main St Ste 1145, San Francisco, Cal...Phone Number
(415) 562-8117Website
www.cleavetherapeutics.comRevenue
$23.8 MillionIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
2
1
1
1
1
1
About Cleave Therapeutics
Cleave Therapeutics is a clinical-stage biopharmaceutical company focused on VCP/p97 as a novel target in protein homeostasis and cellular stress pathways for therapeutic use in cancer. The privately held company, based in San Francisco, is studying CB-5339, its second-generation, small molecule VCP/p97 inhibitor, in a Phase 1 clinical trial in patients with acute myeloid leukemia and myelodysplastic syndrome, while the National Cancer Institute is sponsoring and evaluating CB-5339 in a Phase 1 clinical trial of patients with solid tumors and lymphomas. Cleave investors include 5AM Ventures, Bristol-Myers Squibb, Orbimed, U.S. Venture Partners (USVP), Arcus Ventures, Astellas Venture Management, and Osage University Partners.Explore more
Cleave Therapeutics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Cleave Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Product Launch: Get notified when Cleave Therapeutics launches new products
Cleave Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Earning: See what the market has to say on Cleave Therapeutics recently announced quarterly report
Funding: Get notified immidiatlly once Cleave Therapeutics has new funding data
Check out if Cleave Therapeutics is spiking on competitors!
Website visits: Recent activity has been detected on your website
Click to see if Cleave Therapeutics had a recent Job posting/layoffs
Congratulate Masked Content for being promoted to Masked Content at Cleave Therapeutics
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check if Cleave Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Recommended Actions
Find VP level buyers at Cleave Therapeutics
Find more new buyers
Compare Similar Companies to Cleave Therapeutics
Compare insights from companies similar to Cleave Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Cleave Therapeutics
$23.8M
11-50
Private
$93M
2011
SV
Sujatha Venugopal-PrasadDirector, Clinical Operations
Company Profile Activity
Activity Insights
Cleave Therapeutics is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Cleave Therapeutics is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Cleave Therapeutics.
Cleave Therapeutics financials insights
Gather financial insights about Cleave Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2011
Series A
$44M
2016
Series B
$37M
2019
Private Equity
$12M
Cleave Therapeutics Tech Stack
A closer look at the technologies used by Cleave Therapeutics
See more technologies
Cleave Therapeutics News & Media
CASI PHARMACEUTICALS AND CLEAVE THERAPEUTICS ANNOUNCE CLINICAL TRIAL APPLICATION APPROVAL FOR CB-5339 IN PATIENTS WITH MULTIPLE MYELOMA IN CHINA
~ NMPA approved CB-5339 CTA for Multiple Myeloma indication ~ ~ Expected enrollment to begin in 2023 ~ ROCKVILLE, Md. and BEIJING, Jan. 6, 2023 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company focused on developing and commercializing innovative...Cleave Therapeutics Licenses First-in-Class VCP/P97 Inhibitor CB-5339 To CASI Pharmaceuticals For Greater China Region
SAN FRANCISCO and ROCKVILLE, Md., March 8, 2021 /PRNewswire/ -- Cleave Therapeutics, Inc. ("Cleave"), a clinical-stage biopharmaceutical company focused on valosin-containing protein (VCP)/p97 as a novel target in protein homeostasis, DNA damage response and other cellular stress pathways...Cleave Therapeutics Announces Preclinical Research Collaboration With Jazz Pharmaceuticals in Acute Myeloid Leukemia (AML)
SAN FRANCISCO--(BUSINESS WIRE)--Cleave Therapeutics Announces Research Collaboration with Jazz Pharmaceuticals in Acute Myeloid Leukemia (AML)Cleave Therapeutics Announces Commencement of a Phase 1 Clinical Study of CB-5339, A Valosin-Containing Protein (VCP)/p97 Inhibitor, in Patients with Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)
SAN FRANCISCO--(BUSINESS WIRE)--Cleave Therapeutics Begins Phase 1 Trial of CB-5339 in Patients with Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Cleave Therapeutics
Sign Up For FreeTo access detailed company insights
Cleave Therapeutics is a clinical-stage biopharmaceutical company focused on VCP/p97 as a novel target in protein homeostasis and cellular stress pathways for therapeutic use in cancer. The privately held company, based in San Francisco, is studying CB-5339, its second-generation, small molecule VCP/p97 inhibitor, in a Phase 1 clinical trial in pat... Read More
